Trial Profile
A PHASE 1, OPEN-LABEL DOSE-FINDING STUDY TO EVALUATE SAFETY, TOLERABILITY, AND IMMUNOGENICITY AND PHASE 2/3 PLACEBO-CONTROLLED, OBSERVER-BLINDED SAFETY, TOLERABILITY, AND IMMUNOGENICITY STUDY OF A SARS-COV-2 RNA VACCINE CANDIDATE AGAINST COVID-19 IN HEALTHY CHILDREN
Status:
Completed
Phase of Trial:
Phase II/III
Latest Information Update: 11 Jan 2024
Price :
$35
*
At a glance
- Drugs Tozinameran (Primary)
- Indications COVID 2019 infections
- Focus Adverse reactions; Pharmacodynamics; Registrational
- Sponsors BioNTech
- 18 Dec 2023 Status changed from active, no longer recruiting to completed.
- 07 Nov 2023 Planned End Date changed from 11 Oct 2023 to 22 Nov 2023.
- 12 Sep 2023 Planned End Date changed from 16 Oct 2023 to 11 Oct 2023.